// App-Quantinova.ai

1813 : Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy Results of Enigma 2 Study

Researchers

Presenter

  • Racil Zdenek

Principal Investigators

  • Petra Belohlavkova

  • Petr Cetkovsky

  • Edgar Faber

  • Hana Klamova

  • Malaskova Ludmila

  • Tomasz Sacha

  • Voglova Jaroslava

  • Daniela Zackova

  • Pavel Zak

  • Jiri Mayer

Medical Centers

  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Dept. Clinical Biochemistry, St. Anne University Hospital Brno, Brno, Czech Republic

  • 4th Department of Internal Medicine-Hematology, Charles University and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Masaryk University Hospital, Brno, Czech Republic

  • Dept. of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic,

Locations

  • Poland

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved